Animal model
Maus / Ratte
Philp D et al. 2003
Accelerated wound and tissue healing
What does NOT follow: Animal-model finding — no confirming controlled human studies.
Peptide entry · Healing
TB-500
Thymosin Beta-4 Fragment · LKKTETQ · Ac-LKKTETQ
Highest evidence
Animal model
Studies recorded
3
Legal status · US
Research onlyScientific context only. Not medical advice, not a recommendation to use.
At a glance
Synthetic fragment of the endogenous protein Thymosin Beta-4, specifically the actin-binding sequence. Preclinical models investigate effects on cell migration, neovascularisation and wound healing — robust human data are absent.
Researched for
Wound healingTendon and ligament healingAngiogenesisAnti-inflammatory effects
Official status
US: Research only
Not approved as a medicinal product; marketed only as a research chemical.
01
Mechanism of action
Synthetic fragment of the endogenous protein Thymosin Beta-4. In preclinical models, an influence on cell migration, actin sequestration and neovascularisation has been described. Robust human pharmacokinetic data are not publicly available.
02
Evidence at a glance
Reading note. The distribution shows on which evidence tier each observation sits. Strong colours mark stronger evidence — weaker tiers are deliberately visible, not hidden.
03
What the studies show
In vitro
Zellkultur
Malinda KM et al. 1997
Promotion of angiogenesis via actin binding
What does NOT follow: In-vitro observation; says nothing about clinical efficacy.
Animal model
Maus
Sosne G et al. 2010
Anti-inflammatory effects
What does NOT follow: Preclinical; cannot be transferred to humans without clinical studies.
Theoretical
—
Promotion of hair growth
What does NOT follow: No controlled human studies — popular claim without robust evidence.
04
Where studies disagree
Open question
Is TB-500 (Ac-LKKTETQ) pharmacologically equivalent to full-length Thymosin Beta-4?
POSITION A
Animal models show comparable wound-healing effects — the actin-binding domain reproduces central mechanisms.
POSITION B
The full-length protein binds additional targets and has different pharmacokinetic properties. Studies directly comparing fragment vs. full-length are scarce.
CURRENT STATE · Effect equivalence is plausible for certain endpoints but not established. Direct comparison trials are lacking.
05
Pharmacokinetics
No robust pharmacokinetic human data available. A model curve is not invented.
06
Routes of administration in the literature
Which routes of administration the available studies describe — neutral reporting, not a usage guide.
Subcutaneous
Most common route in preclinical studies.
Intramuscular
Described in some animal models; pharmacokinetic comparative data limited.
Topical
Locally applied in dermatological wound-healing models.
07
Known adverse events from studies
Factual reporting of what studies observed. Not a safety statement for individual use.
Animal model
Animal models
Injection-site reactions
Animal-model observation. Human frequency unknown — no controlled human trials.
vereinzelt / sporadic
Theoretical
Theoretical risk of proliferative effects due to angiogenic activity
Inferred from mechanism of action, not established from clinical data. No tumour promotion observed in published animal studies — but long-term human data are absent.
07b
Interactions & combinations
Documented interactions and contraindications from studies, prescribing information and guidelines. Where no data exists, this is stated.
Reporting of risks, NOT a combination guide. The absence of an entry does not mean „safe to combine“ but „not sufficiently studied“.
No documented interactions recorded
We have not yet found robustly documented interactions for this peptide. This does NOT mean none exist — the data is limited.
08
Risks & hygiene aspects in the literature
What regulatory and scientific literature reports on risks, sterility and identity in non-pharmaceutical sources — descriptive, not a hygiene guide.
WADA status
The World Anti-Doping Agency lists TB-500 as a prohibited substance on the Prohibited List — relevant for competitive sport. Factual reporting of the regulation.
Purity and identity issues in non-pharmaceutical sources
Published analyses of grey-market TB-500 products show substantial variation in actual peptide content and sequence identity. No pharmaceutical quality control.
09
Regulatory voices
Direct statements from official assessment documents — paraphrased with date and source link.
WADAWorld Anti-Doping Agency
2024-01Status on the Prohibited List
TB-500 / Thymosin Beta-4 is listed on the WADA Prohibited List among the banned substances — relevant for competitive sport and in many federations also out of competition.
10
Anecdotal observations
Weakest evidence tier — not supported by studies
Reading note. This section gathers popular claims from communities and forums. They are explicitly marked as weakest-tier evidence. Unblinded self-reports are particularly prone to placebo, recall and confirmation biases.
Why no amounts or protocols are listed here. We deliberately show only WHAT communities report — not in what amount or how it is used. Anecdotal "doses" or "biohacker protocols" are neither verified nor standardised nor safe; publishing them would be a usage guide, which we do not provide on principle. Specific amounts belong in a conversation with a doctor, not in a forum.
Faster recovery from muscle and tendon injuries
Common claim in sports and bodybuilding communities
Not supported by studies: Not supported by controlled human trials. Self-reports without blinding are particularly prone to placebo and expectation effects.
Promotion of scalp hair growth
Occasionally discussed in hair-loss communities
Not supported by studies: No robust human studies on hair growth with TB-500 have been published.
11
Legal status by country
12
Reconstitution calculator
Pure mg/mL maths — works like a calculator. Not a usage recommendation.
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
- 1Enter the vial's substance amount (printed on the label).
- 2Enter how much solvent you add.
- 3Result = concentration in mg per mL.
Printed on the label
/
Liquid you add
=
2.50
mg / mL
5 mg in 2 mL gives 2.50 mg/mL — each millilitre contains 2.50 mg of substance.
14
Study register
Animal model
Philp D et al. · 2003
Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice
In vitro
Malinda KM et al. · 1997
Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells
Preclinical
Sosne G et al. · 2010
Thymosin beta4 and corneal wound healing: visions of the future
15
Sources & method
Reviewed by
Dr. [Placeholder]
Last reviewed
2026-05-21
Get new studies on TB-500
Science only, no sales. Unsubscribe anytime.